Cell Signaling Technology Logo - Extra Large
View Featured Offers >>
  1. Products /
  2. Primary Antibodies /
  3. KIAA1549 Antibody

KIAA1549 Antibody #79092

Filter:
  • WB
  • IP

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 90
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    KIAA1549 Antibody recognizes endogenous levels of total KIAA1549 protein. This antibody detects KIAA1549::B-Raf fusion proteins containing KIAA1549 exons 15 and 16. This antibody is predicted to detect v1 long, v1 short, v2 long, and v2 short isoforms of human KIAA1549.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1405 of human KIAA1549 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    KIAA1549 is a multi-pass membrane protein primarily expressed in the central nervous system and enriched in the connecting cilium of photoreceptors (1). The human KIAA1549 gene consists of 20 exons, with an alternate promoter within intron 8 and a variable splicing site within intron 19, yielding two short and two long isoforms (1,2). The long isoform is primarily expressed in brain tissue, and the short isoform is almost exclusively expressed in retina (1). While the endogenous function of KIAA1549 protein is still not well understood, homozygous mutations in the short KIAA1549 isoform have been observed in retinitis pigmentosa patients (1). Aberrant tandem duplications in chromosomal region 7q34 cause the expression of a novel fusion protein, combining the KIAA1549 N-terminus with the B-Raf C-terminus (2,3). The most common fusion observed is between KIAA1549 exons 1-16 and BRAF exons 9-18, though additional fusion combinations have been observed (2-4). KIAA1549::B-Raf fusion proteins are the primary drivers of low-grade juvenile pilocytic astrocytomas, the most common glioma in children (2,3). Because the inhibitory N-terminal regions of B-Raf protein are missing in these fusion proteins, unregulated downstream MEK/Erk signaling drives tumor growth (4-6). KIAA1549::B-Raf tumors have demonstrated resistance to several type 1 B-Raf inhibitors, though second-generation B-Raf inhibitors and clinical inhibitors of MEK1/2 have shown promise (7-9).

    Alternate Names

    FLJ11731; FLJ38703; FLJ40644; hypothetical protein LOC57670; K1549; KIAA1549; RP86; UPF0606 protein KIAA1549

    Database Links

    UniProt ID: Q9HCM3


    Entrez-Gene Id: 57670


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.